This finding suggests that IL-2-loaded CAR-T Exos may enhance CD8+ T cell-mediated tumor killing by increasing IL-2 bioavailability in the tumor microenvironment while reducing systemic exposure. This evidence concerns the gene IL2 and neoplasm.